



Amir Jalilian got his Pharm.D. Degree in 1995 with a thesis on heterocycles medicinal chemistry, followed by a Ph. D Degree on Radiopharmaceutical chemistry in 1999 on non-FDG F-18 tracers for oncology. In 1999 he started a post-doctoral fellowship at the University of Alberta, Canada on the development of hypoxia imaging agents followed by another post-doc position at Yale School of Medicine, CT, USA. During the years he was active in the field of research and development of cyclotron and reactor-based radiopharmaceuticals as well as their introduction into the clinical applications. In 2015, he acquired a scientific position at Radioisotope Products and Radiation Technology Section at IAEA, Vienna, Austria. He has more than 350 publications in peer-reviewed journals as well as many other IAEA publications.